iSpecimen Inc. Financing Cash Flow
iSpecimen Inc. (ISPC) reported Financing Cash Flow of $2.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- iSpecimen Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $5.01M, a 32.94% increase year-over-year.
- iSpecimen Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $5.23M, a 508.11% increase year-over-year.
- iSpecimen Inc. net cash provided by (used in) financing activities for the quarter ending 2024-12-31 was $3.77M.
- iSpecimen Inc. net cash provided by (used in) financing activities for the quarter ending 2024-09-30 was $859.98K.
- iSpecimen Inc. net cash provided by (used in) financing activities for fiscal 2025 was $10.24M, a 76.04% increase from fiscal 2024.
- iSpecimen Inc. net cash provided by (used in) financing activities for fiscal 2024 was $5.82M, a 8108.47% increase from fiscal 2023.
- iSpecimen Inc. net cash provided by (used in) financing activities for fiscal 2023 was $70.89K.
- iSpecimen Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$3.42M, a 108.83% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.29M 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $5.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $10.24M derived: sum of 2 quarters · filed 2026-04-01 | $10.24M 10-K · filed 2026-04-01 | |
| 2025-09-30 | $5.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $5.23M 10-Q · filed 2025-11-17 | ||
| 2025-06-30 | -$1.10K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $4.63M derived: sum of 2 quarters · filed 2026-04-01 | $5.94M derived: sum of 3 quarters · filed 2026-04-01 | $5.82M 10-K · filed 2026-04-01 |
| 2024-09-30 | $859.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $2.17M derived: sum of 2 quarters · filed 2025-11-17 | $2.05M 10-Q · filed 2025-11-17 | $2.05M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.19M 10-Q · filed 2025-08-14 | $1.19M derived: sum of 3 quarters · filed 2025-08-14 | $1.19M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$118.86K 10-Q · filed 2025-05-19 | -$118.86K derived: sum of 2 quarters · filed 2025-05-19 | -$118.86K derived: sum of 3 quarters · filed 2025-05-19 | -$115.70K derived: sum of 4 quarters · filed 2025-05-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-14 | $0.00 derived: sum of 2 quarters · filed 2025-04-14 | $3.15K derived: sum of 3 quarters · filed 2025-04-14 | $70.89K 10-K · filed 2025-04-14 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.15K derived: sum of 2 quarters · filed 2024-11-07 | $70.89K 10-Q · filed 2024-11-07 | -$3.43M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.15K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $70.89K 10-Q · filed 2024-08-06 | -$3.43M derived: sum of 3 quarters · filed 2024-08-06 | -$3.43M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $67.74K 10-Q · filed 2024-05-07 | -$3.43M derived: sum of 2 quarters · filed 2024-05-07 | -$3.44M derived: sum of 3 quarters · filed 2024-05-07 | -$3.43M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$3.50M derived: sum of 2 quarters · filed 2024-03-13 | -$3.50M derived: sum of 3 quarters · filed 2024-03-13 | -$3.42M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$4.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $3.11K derived: sum of 2 quarters · filed 2023-11-02 | $78.39K 10-Q · filed 2023-11-02 | $19.65M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $8.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $83.35K 10-Q · filed 2023-08-02 | $19.66M derived: sum of 3 quarters · filed 2023-08-02 | $22.63M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $75.28K 10-Q · filed 2023-05-04 | $19.65M derived: sum of 2 quarters · filed 2023-05-04 | $22.62M derived: sum of 3 quarters · filed 2023-05-04 | |
| 2021-12-31 | $19.57M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-30 | $22.55M derived: sum of 2 quarters · filed 2023-03-30 | $38.75M 10-K/A · filed 2023-03-30 | |
| 2021-09-30 | $2.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $19.18M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $16.20M 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $250.00K derived: sum of 2 quarters · filed 2022-03-22 | $2.03M 10-K · filed 2022-03-22 | |
| 2020-09-30 | $250.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.03M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $1.78M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |